Overview

RING - Rituximab for Lupus Nephritis With Remission as a Goal

Status:
Unknown status
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6 months of standard of care (SOC). STUDY DESIGN Investigator-initiated randomized international open multicentric 104-week study.
Phase:
Phase 3
Details
Lead Sponsor:
Frédéric A. Houssiau, MD, PhD
Treatments:
Rituximab